Get the Stockscreener App
3.69
9.50%
0.32
After Hours:
3.55
-0.14
-3.79%
Fulcrum Therapeutics Inc stock is traded at $3.69, with a volume of 3.95M.
It is up +9.50% in the last 24 hours and down -47.44% over the past month.
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing small molecules for genetically defined rare diseases. Its product candidate, Pociredir, is an oral small molecule designed to induce fetal hemoglobin (HbF) and is in clinical development for sickle cell disease (SCD). The company completed dosing in the Phase 1b PIONEER trial evaluating pociredir in adults with SCD and reported clinical data showing clinically relevant HbF induction and improvements in markers of hemolysis and anemia. The company has also generated a pipeline of clinical-stage and pre-clinical programs targeting the root causes of rare genetic diseases.
See More
Previous Close:
$3.37
Open:
$3.36
24h Volume:
3.95M
Relative Volume:
2.56
Market Cap:
$245.88M
Revenue:
$80.00M
Net Income/Loss:
$-76.12M
P/E Ratio:
-3.2185
EPS:
-1.1465
Net Cash Flow:
$-63.88M
1W Performance:
-46.68%
1M Performance:
-47.44%
6M Performance:
-58.54%
1Y Performance:
-48.10%
1-Day Range:
$3.30
$3.70
1-Week Range:
$2.83
$7.02
52-Week Range:
$2.83
$15.74
Fulcrum Therapeutics Inc Stock (FULC) Company Profile
Name
Fulcrum Therapeutics Inc
Sector
Industry
Phone
617-651-8851
Address
26 LANDSDOWNE STREET, CAMBRIDGE, MA
Compare FULC vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
FULC
Fulcrum Therapeutics Inc
|
3.69 | 224.55M | 80.00M | -76.12M | -63.88M | -1.1465 |
VRTX
Vertex Pharmaceuticals Inc
|
446.83 | 112.12B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
635.45 | 65.92B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
891.32 | 52.38B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
303.05 | 40.54B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
149.23 | 33.10B | 742.00K | -1.37B | -1.07B | -7.0731 |
Fulcrum Therapeutics Inc Stock (FULC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-12-26 | Initiated | JP Morgan | Overweight |
| Nov-24-25 | Initiated | Truist | Buy |
| Jul-29-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| May-23-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| May-15-25 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Sep-13-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Sep-12-24 | Downgrade | BofA Securities | Neutral → Underperform |
| Sep-12-24 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Sep-12-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Sep-12-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Sep-12-24 | Downgrade | Stifel | Buy → Hold |
| Sep-09-24 | Upgrade | BofA Securities | Underperform → Neutral |
| May-20-24 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-13-24 | Initiated | RBC Capital Mkts | Outperform |
| Sep-25-23 | Initiated | Goldman | Neutral |
| Aug-23-23 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Aug-22-23 | Upgrade | Stifel | Hold → Buy |
| May-04-23 | Downgrade | Goldman | Buy → Neutral |
| Mar-10-23 | Downgrade | Credit Suisse | Outperform → Neutral |
| Mar-10-23 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Mar-09-23 | Downgrade | Stifel | Buy → Hold |
| Feb-28-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-24-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Nov-15-22 | Initiated | Goldman | Buy |
| Mar-08-22 | Initiated | Oppenheimer | Outperform |
| Mar-03-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Aug-11-21 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Mar-22-21 | Initiated | Credit Suisse | Outperform |
| Mar-02-21 | Initiated | Stifel | Buy |
| Oct-16-20 | Initiated | Piper Sandler | Overweight |
| Aug-12-20 | Downgrade | BofA Securities | Neutral → Underperform |
| Aug-12-20 | Reiterated | H.C. Wainwright | Buy |
| Aug-12-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-19-20 | Downgrade | BofA/Merrill | Buy → Neutral |
| Jun-17-20 | Initiated | BTIG Research | Buy |
| Oct-03-19 | Initiated | H.C. Wainwright | Buy |
| Aug-12-19 | Initiated | BofA/Merrill | Buy |
View All
Fulcrum Therapeutics Inc Stock (FULC) Latest News
FULC stock crashes as cancer risk forces its only drug program's end - MSN
Fulcrum plunges after discontinuing lead program - MSN
Kaplan Fox Encourages Investors of Fulcrum Therapeutics, Inc. (NA - The National Law Review
Fulcrum Therapeutics lays off 85% of workforce as it seeks strategic alternatives - The Business Journals
Fulcrum Therapeutics (FULC) loses 51% in 4 weeks, here's why a trend reversal may be around the corner - MSN
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Fulcrum Therapeutics, Inc. (FULC) And Encourages Investors to Reach Out - ACCESS Newswire
A Look At Fulcrum Therapeutics (FULC) Valuation After Scrapping Lead Sickle Cell Drug And Restructuring - Yahoo Finance
Fulcrum Therapeutics (FULC) Loses 51% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Yahoo Finance
Levi & Korsinsky Announces Investigation of Securities Claims Against Fulcrum Therapeutics, Inc. (FULC) - GlobeNewswire
FULC Stock Slumps Nearly 50% After Hours As FDA Kills Only Clinical Program Over Cancer Risk - Stocktwits
Fulcrum Therapeutics Undertakes Major Restructuring, Explores Strategic Alternatives - TipRanks
Fulcrum Therapeutics (FULC) cuts workforce 85% and hires Leerink for strategic review - Stock Titan
Fulcrum Therapeutics, Inc. Engages Leerink Partners LLC as Financial Advisor to Assist in Reviewing Potential Strategic Alternatives - marketscreener.com
FULC Investor Alert: Levi & Korsinsky Investigates Fulcrum Therapeutics, Inc. (FULC) for Potential Securities Fraud - Business Wire
What's Going On With Fulcrum Therapeutics Stock On Thursday? - Benzinga
FULC Downgraded by JP Morgan -- Rating Changed to Underweight - GuruFocus
Fulcrum: 'Hold' On Pociredir Discontinuation And Strategic Alternatives Shift - Seeking Alpha
FULC Stock Crashes as Cancer Risk Forces Its Only Drug Program's End - Yahoo Finance
This Truist Securities Analyst Turns Bearish; Here Are Top 5 Downgrades For Tuesday - Benzinga
FULC SHAREHOLDER INVESTIGATION: SueWallSt Investigates Fulcrum Therapeutics, Inc. for Possible Securities Law Violations - PR Newswire
JPMorgan Downgrades Fulcrum Therapeutics to Underweight From Overweight - marketscreener.com
Goldman Sachs drops Fulcrum Therapeutics stock coverage after trial halt By Investing.com - Investing.com Australia
FULC Downgraded by Stifel -- Price Target Lowered to $3.00 - GuruFocus
Goldman Sachs drops Fulcrum Therapeutics stock coverage after trial halt - Investing.com UK
Goldman Sachs Suspends Rating on Fulcrum Therapeutics (FULC) - GuruFocus
Fulcrum Therapeutics, Inc. Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of Fulcrum Therapeutics, Inc. (FULC) - PR Newswire
Goldman Sachs Drop Coverage of Fulcrum Therapeutics Inc. (FULC) - StreetInsider
FDA Concerns About Cancer Risk Sink Fulcrum Therapeutics’ Sickle Cell Disease Drug - MedCity News
FULC Downgraded by Piper SandlerPrice Target Lowered to $3.00 - GuruFocus
Cantor Fitzgerald Downgrades Fulcrum Therapeutics to Neutral From Overweight - Moomoo
FULC Downgraded by Leerink Partners -- Price Target Lowered to $4.00 - GuruFocus
Fulcrum Therapeutics (FULC) Halts Sickle Cell Drug Development, Stock Plummets - GuruFocus
Fulcrum exploring a potential sale after FDA sidelined its sickle cell drug - BioPharma Dive
Fulcrum Therapeutics, Inc. Shareholders Are Encouraged to - GlobeNewswire
Fulcrum Therapeutics, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information about Potentially Recovering Their Losses - GlobeNewswire Inc.
FULC Downgraded by HC Wainwright & Co. -- Price Target Lowered t - GuruFocus
This Biotech Stock Plunges 54%. Its Sickle Cell Drug Has ‘No Viable Path Forward.’ - Barron's
Fulcrum drops work on SCD drug pociredir; stock plummets - BioWorld News
FULC INVESTOR ALERT: Holzer & Holzer, LLC Investigation of Fulcrum Therapeutics, Inc. - GlobeNewswire
Fulcrum Therapeutics (FULC) Faces Significant Pre-Market Decline - GuruFocus
Fulcrum plummets over 50% after scrapping lead sickle-cell drug on FDA concerns - Reuters
Why is Fulcrum Therapeutics stock collapsing today? By Investing.com - Investing.com Canada
This Goldman Sachs Analyst Turns Bearish; Here Are Top 4 Downgrades For Tuesday - Benzinga
Stifel Downgrades Fulcrum Therapeutics to Hold From Buy, Adjusts PT to $3 From $25 - marketscreener.com
Leerink downgrades Fulcrum Therapeutics stock rating on FDA concerns By Investing.com - Investing.com Canada
Fulcrum falls after dropping lead program (FULC:NASDAQ) - Seeking Alpha
HC Wainwright Downgrades Fulcrum Therapeutics to Neutral From Buy, Adjusts PT to $3 From $25 - marketscreener.com
Leerink Partners Downgrades Fulcrum Therapeutics to Market Perform From Outperform, Adjusts PT to $4 From $24 - marketscreener.com
Fulcrum Therapeutics (FULC) Faces Downgrade Amid Development Halt - GuruFocus
Truist cuts Fulcrum Therapeutics stock rating after FDA concerns By Investing.com - Investing.com Nigeria
Piper Sandler cuts Fulcrum Therapeutics stock rating on program halt - Investing.com
Fulcrum Therapeutics Inc Stock (FULC) Financials Data
Revenue
Net Income
Cash Flow
EPS
Fulcrum Therapeutics Inc Stock (FULC) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Gould Robert J | Director |
Jan 02 '26 |
Sale |
11.87 |
15,000 |
178,089 |
469,864 |
| Oltmans Curtis Gale | Chief Legal Officer |
Dec 15 '25 |
Sale |
12.92 |
3,452 |
44,600 |
10,252 |
1.13%
3.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):